| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Trout Harry R. III | Vice President, Finance | C/O ENANTA PHARMACEUTICALS, INC., 4 KINGSBURY AVENUE, WATERTOWN | /s/ Matthew Kowalsky as attorney-in-fact | 2025-09-08 | 0002085123 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | ENTA | Common Stock | 10.9K | Aug 26, 2025 | Direct | F1 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | ENTA | Stock Option (right to buy) | Aug 26, 2025 | Common Stock | 7.11K | $81.20 | Direct | F2 | ||||||
| holding | ENTA | Stock Option (right to buy) | Aug 26, 2025 | Common Stock | 10K | $63.35 | Direct | F2 | ||||||
| holding | ENTA | Stock Option (right to buy) | Aug 26, 2025 | Common Stock | 4.99K | $43.57 | Direct | F2 | ||||||
| holding | ENTA | Stock Option (right to buy) | Aug 26, 2025 | Common Stock | 6.05K | $75.33 | Direct | F3 | ||||||
| holding | ENTA | Stock Option (right to buy) | Aug 26, 2025 | Common Stock | 5.57K | $45.00 | Direct | F4 | ||||||
| holding | ENTA | Stock Option (right to buy) | Aug 26, 2025 | Common Stock | 9.08K | $8.99 | Direct | F5 | ||||||
| holding | ENTA | Stock Option (right to buy) | Aug 26, 2025 | Common Stock | 10.2K | $8.83 | Direct | F6 |
| Id | Content |
|---|---|
| F1 | Consists of 762 shares of common stock held by the reporting person and 10,150 shares of common stock underlying unvested restricted stock units ("RSUs") granted under the Enanta Pharmaceuticals, Inc. ("Enanta") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Enanta common stock. The RSUs will vest and settle as follows: (i) 359 RSUs will vest and settle on December 1, 2025, (ii) 1,300 RSUs will vest and settle in two substantially equal annual installments beginning on December 4, 2025, (iii) 3,403 RSUs will vest and settle in three substantially equal annual installments beginning on December 4, 2025, and (iv) 5,088 RSUs will vest and settle in four substantially equal annual installments beginning on December 1, 2025. |
| F2 | 100% of the shares subject to the option are fully vested and exercisable. |
| F3 | Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 19, 2021). |
| F4 | Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 23, 2022). |
| F5 | Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023). |
| F6 | Such option has or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 27, 2024). |
Exhibit 24 Power of Attorney filed herewith.